

10. Crystalline rilapladib characterized by at least two properties, selected from an XRPD pattern according to any one of claims 1-3, a Raman spectrum according to any one of claims 4-6, a melting point according to claim 7, and an ATR-IR absorption spectrum according to claim 8 or 9.
- 5 11. Crystalline rilapladib according to any one of the preceding claims, wherein said crystalline rilapladib is anhydrous.
12. A pharmaceutical composition comprising crystalline rilapladib according to any one of
10 Claims 1-11 and a pharmaceutically acceptable carrier.
13. A method for treating an Lp-PLA₂ mediated disease or disorder in a subject comprising administering to the subject an effective amount of crystalline rilapladib according to any one of Claims 1-11.
- 15 14. The method according to claim 13 wherein the disease or disorder is Alzheimer's Disease.
15. The method according to claim 13 or 14 wherein the subject is a human.
- 20 16. The method according to claim 14 wherein the crystalline rilapladib according to any one of Claims 1-11 is administered in a combination therapy with one or more additional pharmaceutical agents for the treatment of Alzheimer's disease (e.g., agents selected from acetylcholinesterase inhibitors, NMDA receptor antagonists, and combinations thereof, e.g. tacrine, donepezil, rivastigmine, galantamine, and memantine).
- 25 17. Crystalline rilapladib according to any one of claims 1-11 for use in therapy.
18. Crystalline rilapladib according to any one of claims 1-11 for treating an Lp-PLA₂ mediated disease or disorder.
- 30 19. Crystalline rilapladib according to any one of claims 1-11 for treating Alzheimer's Disease.

10. Crystalline rilapladib characterized by at least two properties, selected from an XRPD pattern according to any one of claims 1-3, a Raman spectrum according to any one of claims 4-6, a melting point according to claim 7, and an ATR-IR absorption spectrum according to claim 8 or 9.

5

11. Crystalline rilapladib according to any one of the preceding claims, wherein said crystalline rilapladib is anhydrous.

12. A pharmaceutical composition comprising crystalline rilapladib according to any one of claims 1-11 and a pharmaceutically acceptable carrier.

10

13. An effective amount of crystalline rilapladib according to any one of claims 1-11 for use in the treatment of a Lp-PLA₂ mediated disease or disorder in a subject.

14. The effective amount of crystalline rilapladib according to claim 13 wherein the disease or disorder is Alzheimer's Disease.

15

15. The effective amount of crystalline rilapladib according to claim 13 or 14 wherein the subject is a human.

20

16. The effective amount of crystalline rilapladib according to claim 14 wherein the crystalline rilapladib according to any one of claims 1-11 is to be administered in a combination therapy with one or more additional pharmaceutical agents for the treatment of Alzheimer's disease (e.g., agents selected from acetylcholinesterase inhibitors, NMDA receptor antagonists, and combinations thereof, e.g. tacrine, donepezil, rivastigmine, galantamine, and memantine).

25

17. Crystalline rilapladib according to any one of claims 1-11 for use in therapy.

18. Crystalline rilapladib according to any one of claims 1-11 for treating an Lp-PLA₂ mediated disease or disorder.

30

19. Crystalline rilapladib according to any one of claims 1-11 for treating Alzheimer's Disease.